Zymeworks(ZYME) - 2025 Q1 - Earnings Call Presentation

Pipeline and Technology - Zymeworks has a differentiated pipeline of multifunctional therapeutics targeting solid tumor oncology and autoimmune & inflammatory diseases [8] - The company's ADC technologies combine antibodies with potent payloads for targeted delivery [7] - MSAT technology enhances therapy precision and efficacy, targeting complex disease mechanisms [7] - Zymeworks is advancing next-generation T cell engagers to overcome biological challenges [35] Zanidatamab and Partnerships - Zanidatamab has a potential peak sales of over $2 billion [22] - Zymeworks has a licensing agreement with Jazz Pharmaceuticals, eligible for up to $500 million in regulatory milestones and $862.5 million in commercial milestones [25] - Zymeworks has a licensing agreement with BeiGene, eligible for up to $164 million in development and commercial milestones [25] - Royalties from Jazz are tiered between 10-20%, and from BeiGene, from the high single digits to 19.5% [25] Financials and Milestones - Zymeworks has approximately $321.6 million in cash resources [7] - The company anticipates potential regulatory decisions in the EU and China for zanidatamab in 2L BTC in 2025 [167] - Zymeworks expects an IND submission for ZW251 (GPC3) by mid-2025 [167]